Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pepto-Bismol's hidden power: reshaping your gut bugs?

NCT ID NCT05930197

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how bismuth subsalicylate (the active ingredient in Pepto-Bismol) changes the bacteria in the gut. 34 healthy adults took the medicine for 2 days, and researchers compared their stool samples before and after. The goal was to learn more about how this common stomach medicine affects the gut microbiome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

34 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2024

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: An individual must meet all the following criteria to be eligible for this study: * Aged 18 to 50 years. * In generally good health. * Able to provide informed consent. * Willing to allow samples and data to be stored and shared for future research. * Participants who can become pregnant must agree to use one effective method of contraception when engaging in sexual activities that can result in pregnancy, beginning at the signing of the informed consent form (as early as week -18) until the final study visit. Acceptable methods of contraception include the following: * External or internal condom with spermicide. * Diaphragm or cervical cap with a spermicide. * Hormonal contraception. * Intrauterine device. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Use of systemic antibiotics in the last 3 months. * BSS use in the last 3 months. * Pregnant or breastfeeding. * Allergy to BSS. * Allergy to other salicylates (including aspirin). * Current use of other salicylates (including aspirin). * Current use of anticoagulant medications. * History of or active GI ulcers. * History of or active bleeding disorder. * Bloody stool within the last 3 months. * Diarrhea within the last 2 weeks (defined as three or more loose or liquid stools per day). * Current use of medications that may have a drug interaction with BSS. * Not proficient in written English. * Currently participating in another clinical trial that may affect current study procedures, per investigator s discretion. * Any condition that, in the opinion of the study team, contraindicates participation in this study. Co-enrollment in other studies is restricted. Consideration for co-enrollment in clinical trials evaluating the use of a licensed medication will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.